Drugs / Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03332095 | Jul 2018 → Aug 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-27 | Merck Sharp & Dohme LLC | Results Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021 merck.com ↗
Phase 2b data through 144 weeks demonstrated that islatravir combined with doravirine continued to maintain viral suppression, as measured by the number of study participants achieving HIV-1 RNA levels <50 copies/mL, similar to DOR/3TC/TDF. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-27 | Merck Sharp & Dohme LLC | Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021 merck.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03332095 ↗ |
| Known as | DOR/3TC/TDF | “Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)” NCT03332095 ↗ |
| Route | Oral | “DOR/3TC/TDF administered orally as a fixed-dose combination” NCT03332095 ↗ |